HLA-C and neoplasm: Furthermore, compared to small-molecule inhibitors, which typically target specific proteins or signaling pathways within cancer cells, TCR-T cell therapy offers the ability to target tumor cells more selectively by recognizing specific peptide-MHC complexes that are often unique to cancer cells.